PRO: Patients With Chronic Hepatitis B in Immune‐Tolerant Phase Should Be Treated
Jagpal Singh Klair, James Vancura, Arvind R. Murali – 25 February 2020
Use of Statins in Patients With and Without Liver Disease
Prashanth Francis, Lisa Forman – 25 February 2020
Nutritional Management of Cholestasis
Stephanie R. Send – 25 February 2020
Donor‐Specific Antibodies in Liver Transplantation
Kathy M. Nilles, Josh Levitsky – 25 February 2020
Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation
Chuyue Tu, Hui Xiong, Yufeng Hu, Wen Wang, Gui Mei, Hua Wang, Ya Li, Zelin Zhou, Fengping Meng, Peng Zhang, Zhinan Mei – 25 February 2020
Behavioral Treatment for Patients With Alcohol‐Related Liver Disease: A Primer for Hepatologists
Peng‐Sheng Ting, Jason Wheatley, Po‐Hung Chen – 25 February 2020
CON: All Patients With Immune‐Tolerated Hepatitis B Virus Do Not Need to Be Treated
Bashar M. Attar – 25 February 2020
Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models
Yan Zhu, Lawrence N. Kwong – 24 February 2020
Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular‐Cholangiocarcinoma in the Setting of Cirrhosis
Eleonora De Martin, Michael Rayar, Nicolas Golse, Margot Dupeux, Maximiliano Gelli, Viviane Gnemmi, Marc Antoine Allard, Daniel Cherqui, Antonio Sa Cunha, Rene Adam, Audrey Coilly, Teresa Maria Antonini, Catherine Guettier, Didier Samuel, Karim Boudjema, Emmanuel Boleslawski, Eric Vibert – 24 February 2020 – This multicenter study compares the outcomes of patients with cirrhosis undergoing liver transplantation (LT) or liver resection (LR) between January 2002 and July 2015 who had intrahepatic cholangiocarcinoma (iCCA) or combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA) found incident
Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis
Maxime G. Zermatten, Montserrat Fraga, Darius Moradpour, Debora Bertaggia Calderara, Alessandro Aliotta, Guido Stirnimann, Andrea De Gottardi, Lorenzo Alberio – 23 February 2020 – In the setting of liver cirrhosis (LC), profound hemostatic changes occur, which affect primary hemostasis, coagulation, and fibrinolysis. They involve prohemorrhagic and prothrombotic alterations at each of these steps. Patients with cirrhosis exhibit multifactorial thrombocytopenia and in vitro thrombocytopathy, counterbalanced by increased von Willebrand factor.